A guide to therapeutic decision-making in patients with non-ST-segment elevation acute coronary syndromes

Journal of the American College of Cardiology

Volumn 41, Issue 4 SUPPL. 4, 2003, Pages S123-S129

  Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 ANTIGEN; CLOPIDOGREL; DALTEPARIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LAMIFIBAN; LOW MOLECULAR WEIGHT HEPARIN; MESSENGER RNA; NITRIC ACID DERIVATIVE; PHOSPHOLIPASE A2; PYRIDINE DERIVATIVE; THROMBOSPONDIN; TIROFIBAN; TROPONIN; VASCULAR CELL ADHESION MOLECULE 1;

ARTERY INJURY; ARTIFICIAL EMBOLISM; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DIABETES MELLITUS; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; INFLAMMATION; MEDICAL DECISION MAKING; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; ST SEGMENT ELEVATION;

EID: 0037454074     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0735-1097(02)02689-x     Document Type: Review

References (40)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-26.
2. Blankenberg S, Rupprecht HJ, Bickel C, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001;104:1336-42.
3. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999;100:793-8.
4. Ridker PM. Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med 1999;130:933-7.
5. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 2001;103:1718-20.
6. Lindemann S, Tolley ND, Dixon DA, et al. Activated platelets mediate inflammatory signaling by regulated interleukin-1 beta synthesis. J Cell Biol 2001;154:485-90.
7. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-4.
8. Mutin M, Canavy I, Blann A, Bory M, Sampol J, Dignat-George F. Direct evidence of endothelial injury in acute MI and unstable angina by demonstration of circulating endothelial cells. Blood 1999;93:2951-8.
9. Topol EJ, Yadav J. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000;101:570-80.
10. Eguchi H, Ikeda H, Murohara T, et al. Endothelial injuries of coronary arteries distal to thrombotic sites: role of adhesive interaction between endothelial P-selectin and leukocyte sialyl lewis. Circ Res 1999;84:525-35.
11. Welch RD, Zalenski RJ, Frederick PD, et al, for the National Registry of MI 2 and 3 Investigators. Prognostic value of a normal or nonspecific initial electrocardiogram in acute MI. JAMA 2001;286:1977-84.
12. Heidenreich PA, Alloggiamento T, Melsop K, McDonald KM, Go AS, Hlatky MA. The prognostic value of troponin in patients with non-ST-elevation acute coronary syndromes: a meta-analysis. J Am Coll Cardiol 2001;38:478-85.
13. Lindahl B, Venge P, Wallentin L, for the FRagmin In unstable Coronary artery disease (FRISC) Study Group. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. J Am Coll Cardiol 1997;29:43-8.
14. Morrow DA, Antman EM, Tanasijevic M, et al. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. J Am Coll Cardiol 2000;36:1812-7.
15. Heeschen C, Hamm CW, Goldman B, Deu A, Langenbrink L, White HD, for the PRISM Study Investigators. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet 1999;354:1757-62.
16. Newby LK, Ohman EM, Christenson RH, et al., for the PARAGON-B Steering Committee. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin-T positive status: the PARAGON-B troponin-T substudy. Circulation 2001;103:2891-6.
17. Morrow DA, Cannon CP, Rifai N, et al., for the Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy (TACTICS) TIMI 18 Investigators. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST-elevation MI. JAMA 2001;286:2405-12.
18. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. The clopidogrel in unstable angina to prevent recurrent events trial investigators: effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
19. The GUSTO IV-ACS Investigators. Glycoprotein IIb/IIIa receptor blocker abciximab does not improve outcome in patients with acute coronary syndromes without early coronary revascularization. Lancet 2001;357:915-24.
20. FRISC II Investigators. Long-term low-molecular-mass heparin in unstable coronary artery disease: FRISC II prospective randomized multicenter study. Lancet 1999;354:701-7.
21. Cohen M, Theroux P, Weber S, et al. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol 1999;71:273-81.
22. Cohen M, Theroux P, Frey MJ, et al. Anti-thrombotic combination using tirofiban and enoxaparin: the ACUTE II study. Circulation 2000;102:II826.
23. Mukherjee D, Mahaffey KW, Sparapani R, et al. The promise of combined LMW heparin and platelet glycoprotein IIb/IIIa inhibition - results from PARAGON B. Circulation 2000;102:II591.
24. Antman E, Bigonzi F, Gibson M, et al. Enoxaparin with or without GP IIb/IIIa inhibition as reperfusion strategy in ST-segment elevation MI - results of the ENTIRE-TIMI 23 trial (abstr). Eur Heart J 2001;Suppl:22:15.
25. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment elevation acute coronary syndromes. Circulation 2001;104:2767-71.
26. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol 1998;31:1460-5.
27. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease: FRISC study group (FRagmin during InStability in Coronary artery disease). N Engl J Med 2000;343:1139-47.
28. Bayes-Genis A, Conover CA, Overgaard MT, et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001;345:1022-9.
29. Lindahl B, Diderholm E, Lagerqvist B, Venge P, Wallentin L, and The FRISC II (Fast Revascularization during InStability in CAD) investigators. Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. J Am Coll Cardiol 2001;38:979-86.
30. Montalescot G, Collet JP, Lison L, et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000;36:110-4.
31. Montalescot G, Philippe F, Ankri A, et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. Circulation 1998;98:294-9.
32. Lincoff AM, Kereiakes DJ, Mascelli MA, et al. Abciximab suppresses the rise in levels of circulation inflammatory markers following percutaneous coronary revascularization. Circulation 2001;104:163-7.
33. Chew DP, Bhatt DL, Robbins MA, et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol 2001;88:672-4.
34. Feldman M, Jialal I, Devaraj S, Cryer B. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol 2001;37:2036-41.
35. Moshfegh K, Redondo M, Julmy F, et al. Antiplatelet effects of clopidogrel compared with aspirin after MI: enhanced inhibitory effects of combination therapy. J Am Coll Cardiol 2000;36:699-705.
36. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation MI. J Am Coll Cardiol 2000;36:959-1062.
37. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST-elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000;284:835-42.
38. Topol EJ, Moliterno DJ, Herrmann HC, et al, for the TARGET Investigators. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary intervention. N Engl J Med 2001;344:1888-94.
39. Cohen M, Demers C, Gurfinkel EP, et al., for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events (ESSENCE) Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-52.
40. Antman EM, McCabe CH, Gurfinkel EP, et al., for the TIMI 11b Investigators. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave MI: results of the Thrombolysis In MI (TIMI) 11b trial. Circulation 1999;100:1593-601.